Fleroxacin in the treatment of chancroid: an open study in men seropositive or seronegative for the human immunodeficiency virus type 1.
View/ Open
Date
1993Author
Tyndall, MW
Plourde, PJ
Agoki, E
Malisa, W
Ndinya-Achola, JO
Plummer, FA
Ronald, AR
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Fleroxacin was prescribed to treat both HIV-negative and HIV-positive men with proven chancroid in an open study. HIV-negative men were treated with a single 400-mg dose of fleroxacin, and HIV-positive men were treated with 400 mg daily for 5 days. Three of the 58 evaluable HIV-negative men were clinical and microbiologic failures, and two of the 22 evaluable HIV-positive men had persisting infection with Haemophilus ducreyi. Both regimens were well tolerated. Fleroxacin is an acceptable alternative to existing treatment regimens for chancroid in men
URI
http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/8452188http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16981
Citation
Am J Med. 1993 Mar 22;94(3A):85S-88SPublisher
WHO Collaborating Centre for Research and Training in Sexually Transmitted Diseases University of Nairobi, Kenya
Collections
- Faculty of Health Sciences (FHS) [10377]